Phaseline

Targets › PTGFR

PTGFR (Prostaglandin F2-alpha receptor): drug programs, companies and trials

8 programs from 8 companies in 16 trials: 7 Phase 4, 6 Phase 3, 2 Phase 1, 1 Phase 2; Ophthalmology, Immunology; next expected readout Dec 2026.

Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. (UniProt, P43088)

Open in Phaseline: the race on PTGFR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Copenhagen University Hospital, RigshospitaletMonoprost
Prostaglandin F2α analog
PTGFRPhase 4GlaucomaDec 2026
GlaukosTravoprost
Prostanoid FP receptor agonist
PTGFRPhase 4Glaucoma, Open-Angle; Glaucoma, Open-angle; Glaucoma; Open Angle GlaucomaMay 2027
Prairie Eye CenterRocklatan
Prostaglandin F receptor agonist and Rho kinase inhibitor
PTGFRPhase 4Open Angle Glaucoma–
Federal University of São PauloTriplenex (triple fixed combination)
Triple combination: alpha-2 adrenergic agonist (brimonidine), non-selective beta-blocker (
ADRA2A, ADRB1, ADRB2, PTGFRPhase 4Glaucoma–
YS Life ScienceYSBP
Prostaglandin F (FP) receptor agonist
PTGFRPhase 3Primary Open Angle Glaucoma (POAG)Nov 2027
SpyGlass PharmaBimatoprost
Prostanoid FP receptor agonist
PTGFRPhase 3Cataract; GlaucomaNov 2027
Triple HairTH07
Fixed combination of 5-alpha reductase inhibitor (finasteride), alpha-adrenergic agonist (
SRD5A2, PTGFRPhase 3Androgenic AlopeciaDec 2027
Santen PharmaceuticalDE-117B Eye Drops
Prostaglandin F (FP) receptor agonist
PTGFRPhase 3Open Angle Glaucoma–

Conditions

Glaucoma (5) Cataract (4) Open Angle Glaucoma (3) Glaucoma, Open-Angle (1) Glaucoma, Open-angle (1) Primary Open Angle Glaucoma (POAG) (1) Androgenic Alopecia (1)

Modalities

small molecule (6), mixed (1)

Companies

Federal University of São Paulo (1) Copenhagen University Hospital, Rigshospitalet (1) SpyGlass Pharma (1) Glaukos (1) YS Life Science (1) Prairie Eye Center (1) Santen Pharmaceutical (1) Triple Hair (1)

Related targets

ADRA2A (1) ADRB1 (1) ADRB2 (1) SRD5A2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.